Please login to the form below

Not currently logged in
Email:
Password:

Danish biopharma company wins R&D award

Zealand Pharma has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan

Zealand Pharma A/S has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan, a global growth consulting firm. Zealand Pharma is involved in the discovery and development of innovative peptide-based drugs. It has been ranked top for demonstrating technological superiority in its field through market analysis based on interviews and extensive secondary research.

"It is an honour to be recognised by Frost & Sullivan", said David Solomon, head of Zealand Pharma A/S. "The European Research & Development Award highlights our company's ongoing achievements in its path to commercialising peptide-based drugs that treat unmet medical need in the areas of diabetes, metabolism, cardiovascular disease and gastrointestinal disorders such as Crohn's disease." 

The award recognises the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.

All of Zealand's products target diseases and symptoms of significant unmet clinical need and commercial potential. 

Since 1999, Zealand's scientists have built a pipeline that includes five compounds in clinical development, three of which have been out-licensed to pharmaceutical companies, sanofi-aventis, Wyeth and Helsinn Healthcare.

18th March 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....